Synopsis The use of new combinations of chemotherapy in patients with pancreatic cancer have increased the survival rate, yet the prognosis of this disease remains poor, even for patients who present with early-stage disease. The study reported the safety and efficacy of neoadjuvant combination chemotherapy in patients with resectable pancreatic adenocarcinoma. Moreover, the neoadjuvant combination regimen provided additional therapeutic benefit compared to benefits achieved with adjuvant - only administration .
This week’s Journal Watch discusses a clinical trial from Lancet Gastroenterology Hepatology, “Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomized, open-label, phase 2-3 trial.” Jun 2018. Authors: Reni M, Balzano G, Zanon S, et al. Key Takeaways The use of neoadjuvant combination chemotherapy may be…
